IFNG and gastric cancer: Our study revealed a decrease in IFNγ in patients with gastric cancer at stages I, II, and III of the disease compared with the control group and the group of patients at stage IV (p1–2 < 0.001, p1–3 < 0.001, p1–4 < 0.001, p2–4 = 0.02).